Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Apyx Medical (NASDAQ: APYX) announced it will release its third quarter fiscal 2025 financial results before markets open on Thursday, November 6, 2025.
Management will host a conference call at 8:00 a.m. Eastern Time on November 6 to discuss results and conduct a Q&A. Dial-in numbers are 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 73607. A live webcast will be available and archived in the company’s Investor Relations section.
Contact for investors is Jeremy Feffer at LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). The company sells helium plasma and RF products under the Renuvion, AYON Body Contouring System, and J-Plasma brands, supported by more than 90 clinical publications.
Apyx Medical (NASDAQ: APYX) ha annunciato che pubblicherà i risultati finanziari del terzo trimestre dell'anno fiscale 2025 prima dell'apertura dei mercati giovedì 6 novembre 2025.
La direzione terrà una conference call alle 8:00 ora orientale il 6 novembre per discutere i risultati e rispondere alle domande. I numeri di dial-in sono 800-717-1738 (USA) o 646-307-1865 (internazionale) con il codice di accesso 73607. Sarà disponibile una webcast in diretta, archiviata nella sezione Investor Relations dell'azienda.
Il contatto per gli investitori è Jeremy Feffer di LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). L'azienda commercializza plasma di elio e prodotti RF sotto i marchi Renuvion, AYON Body Contouring System e J-Plasma, supportata da oltre 90 pubblicazioni cliniche.
Apyx Medical (NASDAQ: APYX) anunció que publicará sus resultados financieros del tercer trimestre fiscal de 2025 antes de la apertura del mercado el jueves 6 de noviembre de 2025.
La dirección realizará una conferencia telefónica a las 8:00 a.m. hora del Este el 6 de noviembre para analizar los resultados y realizar una sesión de preguntas y respuestas. Los números de marcación son 800-717-1738 (EE. UU.) o 646-307-1865 (internacional) con el código de acceso 73607. Habrá una transmisión en vivo por webcast y se almacenará en la sección de Relaciones con Inversores de la empresa.
El contacto para inversores es Jeremy Feffer de LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). La empresa comercializa productos de plasma de helio y RF bajo las marcas Renuvion, AYON Body Contouring System y J-Plasma, respaldada por más de 90 publicaciones clínicas.
Apyx Medical (NASDAQ: APYX)는 2025 회계연도 3분기 실적 발표를 시장 개장에 앞서 2025년 11월 6일 목요일에 발표한다고 발표했다.
경영진은 동부 시간 8:00에 있는 컨퍼런스 콜을 11월 6일에 개최하여 실적을 논의하고 Q&A를 진행합니다. 다이얼-in 번호는 800-717-1738 (미국) 또는 646-307-1865 (국제)이며 접근 코드 73607입니다. 라이브 웹캐스트가 제공되며 회사의 투자자 관계 섹션에 보관됩니다.
투자자 문의는 LifeSci Advisors의 제레미 페퍼(Jeremy Feffer) (212-915-2568; jfeffer@lifesciadvisors.com)입니다. 회사는 Renuvion, AYON Body Contouring System, J-Plasma 브랜드 아래 헬륨 플라즈마 및 RF 제품을 판매하며, 90편 이상의 임상 논문으로 뒷받침됩니다.
Apyx Medical (NASDAQ: APYX) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre de l'exercice 2025 avant l'ouverture des marchés le jeudi 6 novembre 2025.
La direction animera une conférence téléphonique à 8h00, heure de l'Est le 6 novembre pour discuter des résultats et répondre à des questions. Les numéros d'accès sont 800-717-1738 (États-Unis) ou 646-307-1865 (international) avec le code d'accès 73607. Une diffusion en direct sera disponible et archivée dans la section Relations avec les investisseurs de l'entreprise.
Le contact pour les investisseurs est Jeremy Feffer de LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). L'entreprise vend des produits à plasma d'hélium et RF sous les marques Renuvion, AYON Body Contouring System et J-Plasma, soutenue par plus de 90 publications cliniques.
Apyx Medical (NASDAQ: APYX) gab bekannt, dass die Ergebnisse des dritten Quartalsdes Geschäftsjahres 2025 vor Markteröffnung am Donnerstag, dem 6. November 2025 veröffentlicht werden.
Das Management wird am 6. November um 8:00 Uhr ostamerikanischer Zeit einen Konferenzanruf abhalten, um die Ergebnisse zu erläutern und eine Fragerunde durchzuführen. Die Einwahlnummern lauten 800-717-1738 (USA) bzw. 646-307-1865 (international) mit dem Zugangscode 73607. Ein Live-Webcast wird verfügbar sein und im Bereich Investor Relations des Unternehmens archiviert.
Der Ansprechpartner für Investoren ist Jeremy Feffer von LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). Das Unternehmen verkauft Helium-Plasma- und RF-Produkte unter den Marken Renuvion, AYON Body Contouring System und J-Plasma, unterstützt durch mehr als 90 klinische Publikationen.
Apyx Medical (NASDAQ: APYX) أعلنت أنها ستصدر نتائجها المالية للربع الثالث من السنة المالية 2025 قبل افتتاح الأسواق يوم الخميس 6 نوفمبر 2025.
ستعقد الإدارة مكالمة مؤتمريّة في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة في 6 نوفمبر لمناقشة النتائج والقيام بجلسة أسئلة وأجوبة. أرقام الاتصال هي 800-717-1738 (الولايات المتحدة) أو 646-307-1865 (دولية) مع رمز الدخول 73607. سيكون هناك بث حي عبر الويب وسيتم أرشفته في قسم علاقات المستثمرين بالشركة.
جهة الاتصال للمستثمرين هي جيفري فافر من LifeSci Advisors (212-915-2568؛ jfeffer@lifesciadvisors.com). تبيع الشركة منتجات بلازما الهيليوم والراديوايف (RF) تحت العلامات Renuvion، AYON Body Contouring System و J-Plasma، مدعومة بأكثر من 90 منشوراً klinياً.
Apyx Medical (NASDAQ: APYX) 宣布将于市场开盘前公布其 2025 财年第三季度的财务业绩，时间为 2025 年 11 月 6 日星期四开市前。
管理层将于 美东时间上午 8:00 在 11 月 6 日召开电话会议，讨论业绩并进行问答。拨号号码为 800-717-1738（美国）或 646-307-1865（国际），访问码为 73607。将提供现场网络广播并在公司的投资者关系板块存档。
投资者联系为 LifeSci Advisors 的 Jeremy Feffer（212-915-2568； jfeffer@lifesciadvisors.com）。公司在 Renuvion、AYON Body Contouring System 和 J-Plasma 品牌下销售氦等离子体和射频产品，并拥有超过 90 份临床出版物。
- None.
- None.
CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, November 6th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 73607. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
FAQ
When will Apyx Medical (APYX) report third quarter fiscal 2025 results?
What time is the Apyx Medical (APYX) Q3 2025 earnings call on November 6, 2025?
How can I join the Apyx Medical (APYX) earnings call by phone on November 6, 2025?
Where can investors watch the Apyx Medical (APYX) November 6, 2025 webcast and archive?
Who is the investor contact for Apyx Medical (APYX) for the November 6, 2025 release?
What products does Apyx Medical (APYX) market that are mentioned in the Q3 2025 release?
